Target Name: MIR502
NCBI ID: G574504
Review Report on MIR502 Target / Biomarker Content of Review Report on MIR502 Target / Biomarker
MIR502
Other Name(s): hsa-miR-502-3p | hsa-mir-502 | microRNA 502 | MIRN502 | mir-502 | hsa-miR-502-5p | MicroRNA 502

MIR502: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

MIR502 (hsa-miR-502-3p) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to study, and various studies have suggested that it may play a crucial role in the development and progression of these diseases.

MIR502 is a microRNA (miRNA), a small non-coding RNA molecule that is known for its ability to interact with and regulate the expression of other genes. It is expressed in a variety of tissues and cells throughout the body and has been shown to play a role in various biological processes, including cell growth, apoptosis, and inflammation.

One of the reasons why MIR502 has become such an attractive target for drug development is its unique expression pattern. Unlike many other miRNAs, MIR502 is expressed in most tissues of the body and its levels are affected by various factors, including growth factors, chemokines, and other signaling molecules. This makes it difficult to predict its effects and to identify potential drug targets.

Another reason why MIR502 is a promising drug target is its involvement in the development and progression of various diseases, including cancer. Several studies have shown that MIR502 is downregulated in various types of cancer and that its levels are associated with poor prognosis. Additionally, MIR502 has been shown to promote the growth and survival of cancer cells, which makes it a potential therapeutic target.

MIR502 has also been shown to play a role in the regulation of cellular processes that are important for the development and progression of cancer. For example, one study published in the journal PLoS found that MIR502 was involved in the regulation of the angiogenic factors, which are molecules that promote blood vessel formation and are often associated with cancer. The study suggested that MIR502 may play a role in the development of cancer by regulating the balance between pro-inflammatory and anti-inflammatory signaling.

Another study published in the journal Oncogene found that MIR502 was involved in the regulation of the T-cell receptor, which is a critical molecule for the development and progression of cancer. The study suggested that MIR502 may play a role in the regulation of T-cell receptor function and that its levels may be affected by various factors, including cancer treatments.

In addition to its potential role in cancer development and progression, MIR502 has also been shown to have potential as a biomarker. Several studies have shown that MIR502 is expressed in various tissues of the body and that its levels are associated with the outcomes of various diseases, including cancer. For example, one study published in the journal Cancer Research found that MIR502 was expressed in various tissues of patients with colorectal cancer and that its levels were associated with the outcomes of the disease, including survival and recurrence.

Overall, MIR502 is a promising drug target and biomarker due to its unique structure and expression pattern, its involvement in the development and progression of various diseases, and its potential as a therapeutic target. Further research is needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: MicroRNA 502

The "MIR502 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR502 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR503 | MIR503HG | MIR504 | MIR5047 | MIR505 | MIR506 | MIR507 | MIR508 | MIR5088 | MIR5089 | MIR509-1 | MIR509-2 | MIR509-3 | MIR5090 | MIR5091 | MIR5092 | MIR5093 | MIR5094 | MIR510 | MIR5100 | MIR511 | MIR511-2 | MIR512-1 | MIR512-2 | MIR513A1 | MIR513A2 | MIR513B | MIR513C | MIR514A1 | MIR514A2 | MIR514A3 | MIR514B | MIR515-1 | MIR515-2 | MIR516A1 | MIR516A2 | MIR516B1 | MIR516B2 | MIR517A | MIR517B | MIR517C | MIR5186 | MIR5187 | MIR5188 | MIR5189 | MIR518A1 | MIR518A2 | MIR518B | MIR518C | MIR518D | MIR518E | MIR518F | MIR5190 | MIR5191 | MIR5192 | MIR5193 | MIR5194 | MIR5195 | MIR5196 | MIR5197 | MIR519A1 | MIR519A2 | MIR519B | MIR519C | MIR519D | MIR519E | MIR520A | MIR520B | MIR520C | MIR520D | MIR520E | MIR520F | MIR520G | MIR520H | MIR521-1 | MIR521-2 | MIR522 | MIR523 | MIR524 | MIR525 | MIR526A1 | MIR526A2 | MIR526B | MIR527 | MIR532 | MIR539 | MIR541 | MIR542 | MIR543 | MIR544A | MIR544B | MIR545 | MIR548A1 | MIR548A1HG | MIR548A2 | MIR548A3 | MIR548AA1 | MIR548AA2 | MIR548AC | MIR548AD